Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Choroba wcześniej nie leczona lub po nieudanym pierwszym cyklu chemioterapii
- •Pacjenci w remisji po maksymalnie 2 kursach leczenia
- •Ogólny stan zdrowia pacjenta pozwala na leczenie (skala ECOG poniżej lub równa 3)
- •Prawidłowa funkcja wątroby (bilirubina do 2,0 mg/dL, bez ucisku nowotworu)
✗ Disqualifies
- •Pacjentki w ciąży lub karmiące piersią
Simplified criteria — AI translation
Trial details
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Farhad Ravandi-Kashani, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.